Oxycodone Hydrochloride Global Market Report 2025

The oxycodone hydrochloride market size has grown steadily in recent years. It will grow from $4.15 billion in 2024 to $4.32 billion in 2025 at a compound annual growth rate (CAGR) of 4%. The historical growth was influenced by an increasing prevalence of chronic pain conditions, a higher volume of surgical procedures, a surge in cancer diagnoses, an expanding aging population, and the escalating incidence of orthopedic ailments.

The oxycodone hydrochloride market size is expected to see steady growth in the next few years. It will grow to $5.01 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. Anticipated drivers of this future growth include the persistent rise in chronic pain cases, an uptrend in post-surgical interventions, more widespread cancer diagnoses, continued growth in the elderly demographic, and a greater occurrence of orthopedic complications. Prominent trends expected during the forecast period encompass the advancement of abuse-deterrent technologies, formulation of extended-release options, integration of pharmacogenomics for personalized treatment, tamper-resistant packaging innovations, and improvements in controlled-release drug delivery systems.

The rising prevalence of chronic pain is anticipated to drive the growth of the oxycodone hydrochloride market. Chronic pain is defined as pain that persists for more than three months and continues beyond the typical healing time of an injury or illness. This growing prevalence is mainly due to increasing rates of obesity, as excess body weight places additional pressure on joints and muscles, leading to conditions such as osteoarthritis and lower back pain. Oxycodone hydrochloride supports chronic pain management by delivering effective relief from moderate to severe pain, improving patient comfort and overall quality of life by targeting pain receptors in the nervous system. For example, in March 2023, the Office for Health Improvement and Disparities, a UK government department, reported that 17.6% of individuals aged 16 and over had a long-term musculoskeletal condition such as arthritis or persistent back or joint problems in 2022, up from 17% in 2021. This trend underscores how the increasing prevalence of chronic pain is contributing to the market growth of oxycodone hydrochloride.

Key players in the oxycodone hydrochloride market are concentrating on the development of advanced products, including combination therapies, to improve pain management while mitigating the risk of opioid dependency. Combination therapies involve using two or more medications together to boost treatment effectiveness, target multiple mechanisms of action, or lower the risk of resistance. For instance, in April 2025, Elite Pharmaceuticals Inc., a US-based pharmaceutical firm, launched a generic version of Percocet (oxycodone hydrochloride and acetaminophen tablets, USP CII). This product is available in three strengths - mg/325 mg, 10 mg/325 mg, and 325 mg tablets - and is used to relieve moderate to moderately severe pain. The formulation combines oxycodone for strong pain relief with acetaminophen to enhance analgesic efficacy. As a Schedule II controlled substance, it has a high potential for abuse and dependence and thus requires strict medical oversight.

In June 2024, Elite Pharmaceuticals Inc., a US-based pharmaceutical company, entered a partnership with Nostrum Laboratories Inc. to acquire three approved abbreviated new drug applications (ANDAs) for generic versions of Norco, Percocet, and Dolophine. This collaboration seeks to broaden their range of generic opioid analgesics, strengthen their presence in pain management, and provide patients with more affordable alternatives to branded pain relief medications. Nostrum Laboratories Inc. is a US-based company that manufactures prescription medications, including an oral solution that combines oxycodone hydrochloride and acetaminophen.

Major players in the oxycodone hydrochloride market are Viatris Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Lupin Ltd, Mallinckrodt Pharmaceuticals Inc., Euroapi SA, Ani Pharmaceuticals Inc., Purdue Pharma LLP, Chattem Chemicals Inc., Mayne Pharma Group Limited, Alvogen Inc., Veranova, Temad Co., Camber Pharmaceuticals, Noramco Inc., Saneca Pharma A.S., Rhodes Pharmaceuticals, and Arevipharma GmbH.

North America was the largest region in the oxycodone hydrochloride market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oxycodone hydrochloride report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oxycodone hydrochloride market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Oxycodone hydrochloride is a potent opioid analgesic used to relieve moderate to severe pain. It works by binding to opioid receptors in the brain and spinal cord to reduce the perception of pain. It is frequently prescribed for managing pain following surgery or injury and for long-term conditions that involve chronic pain.

The primary forms of oxycodone hydrochloride include extended-release tablets, immediate-release tablets, oral solutions, and extended-release capsules. Extended-release tablets are formulated to gradually release the drug over an extended period, ensuring consistent therapeutic levels and minimizing the need for frequent dosing. This medication can be administered orally or through parenteral routes and is widely used to treat various types of pain, such as pain resulting from surgery or cancer. It is distributed through several channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is utilized across various settings such as hospitals, clinics, and home care environments.

The oxycodone hydrochloride market research report is one of a series of new reports that provides oxycodone hydrochloride market statistics, including the oxycodone hydrochloride industry's global market size, regional shares, competitors with the oxycodone hydrochloride market share, detailed oxycodone hydrochloride market segments, market trends and opportunities, and any further data you may need to thrive in the oxycodone hydrochloride market. This oxycodone hydrochloride market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oxycodone hydrochloride market consists of sales of oxycodone injectable formulations, oxycodone nasal sprays, oxycodone suppositories, and percocet. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.